FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, namely to a two-layer tablet for the treatment of HIV infection, where the first layer contains (in mg): intragranular ingredients: sodium dolutegravir - 52.62, D-mannitol - 145.38, microcrystal cellulose - 60.00, povidone K29/32 - 15.00, sodium starch glycolate - 15.00, purified water - q.s.; extragranular ingredients: sodium starch glycolate - 6.00, sodium stearyl fumarate - 6.00; and the second layer contains (in mg): rilpivirine hydrochloride - 27.50, lactose monohydrate - 55.145, sodium croscarmellose - 1.10, povidone K30 - 3.25, polysorbate 20 - 0.35, purified water - q.s., D-mannitol - 57.755, silicated microcrystal cellulose - 40.00, sodium starch glycolate - 12.90, magnesium stearate - 2.00; and also to a method for the treatment of HIV infection including the injection of the specified tablet to a patient.
EFFECT: group of inventions provides increased stability of active components by preventing the disproportion of their salt forms.
2 cl, 16 dwg, 24 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
TWO-LAYER PHARMACEUTICAL DOSAGE FORM OF TABLETS | 2018 |
|
RU2803050C2 |
SCHEMES FOR TREATMENT OF HIV-INFECTIONS AND AIDS | 2018 |
|
RU2784810C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
NEW ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2508105C2 |
PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION | 2013 |
|
RU2648457C2 |
ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2531089C2 |
ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
COMBINED DRUG FOR VIRAL INFECTION THERAPY | 2017 |
|
RU2662160C9 |
NOVEL QUINOLINE DERIVATIVE FOR USE IN TREATING AND PREVENTING VIRAL INFECTIONS | 2016 |
|
RU2723013C2 |
CCR5 ANTAGONIST FOR ENHANCING IMMUNORESTORATIVE THERAPY AND TREATMENT OF OPPORTUNISTIC INFECTION IN PATIENTS WITH HIV | 2007 |
|
RU2420284C2 |
Authors
Dates
2021-09-20—Published
2018-06-27—Filed